15. Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2024
Open accessThe DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index; 86 of the 155 sources its claims cite were checked for support.
Abstract
The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, an interprofessional expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.
Overview
CoChat Summary
TL;DR
This ADA Standards of Care section summarizes clinical practice recommendations for managing diabetes in pregnancy, covering preconception care, glycemic targets, gestational diabetes, preexisting type 1/type 2 diabetes, preeclampsia prevention, and postpartum care. It is a guideline synthesis rather than a primary study, with recommendations graded by available evidence.
Key findings
- Preconception care should target A1C <6.5% (<48 mmol/mol) to reduce congenital anomalies, preeclampsia, macrosomia, and preterm birth; preconception care in preexisting diabetes was associated with lower A1C and reduced birth defects, preterm delivery, perinatal mortality, small-for-gestational-age births, and NICU admissions.
- Pregnancy glucose goals are fasting plasma glucose <95 mg/dL (<5.3 mmol/L) and either 1-h postprandial <140 mg/dL (<7.8 mmol/L) or 2-h postprandial <120 mg/dL (<6.7 mmol/L); A1C goal is <6% (<42 mmol/mol) if achievable without significant hypoglycemia, relaxed to <7% (<53 mmol/mol) if needed. CGM is recommended in type 1 diabetes pregnancy, with target sensor range 63–140 mg/dL (3.5–7.8 mmol/L) and TIR goal >70%.
- For GDM, lifestyle behavior change is essential and may suffice; insulin is preferred when medication is needed. Metformin and glyburide should not be first-line because both cross the placenta; 70–85% of people with GDM by Carpenter-Coustan criteria can manage with lifestyle alone, while glyburide and metformin failed adequate glycemic outcomes in 23% and 25–28% of participants, respectively.
- Postpartum, GDM history should be screened at 4–12 weeks with a 75-g OGTT; lifetime maternal diabetes risk is 50–60%, with a 10-fold increased risk of type 2 diabetes versus no GDM. Lifestyle intervention and metformin reduced progression to diabetes by 35% and 40%, respectively, over 10 years; insulin requirements are often roughly half prepregnancy levels initially postpartum, and one study found they were 34% lower.
Methods
- This is an ADA “Standards of Care in Diabetes—2024” clinical practice guideline section, produced by the ADA Professional Practice Committee, which updates recommendations annually or more frequently as warranted.
- It synthesizes evidence from observational studies, RCTs, systematic reviews, and meta-analyses; no new primary data collection or trial is reported.
- Recommendations are organized across preconception counseling, glycemic goals, glucose monitoring, GDM management, preexisting type 1 and type 2 diabetes, preeclampsia/aspirin, pregnancy drug considerations, and postpartum care.
Limitations
- The paper states there are no adequately powered randomized trials comparing different fasting and postmeal glycemic goals for preexisting diabetes in pregnancy; data are insufficient to support CGM in all people with type 2 diabetes or GDM; long-term safety data for offspring exposed to glyburide are not available; and there are no intervention trials in offspring of mothers with GDM.
- It also notes that the most appropriate hypoglycemia threshold in pregnancy has not been validated, and that observational preconception A1C data are confounded by other self-care behaviors.
- Evident from the text: several recommendations rely on expert opinion or limited evidence, including some graded E, and some management decisions are individualized because of insufficient data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
69 Valid · 3 Not valid · 30 Not checked · 1 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the presence of microvascular complications is associated with higher risk of disease progression and adverse pregnancy outcomes (22).”
What the sources say
- Supportedcites [22] Relph, 2021, Adverse pregnancy outcomes in women with diabetes-related microvascular disease and risks of disease progression in pregnancy: A systematic review and meta-analysis, PLoS Med source
The Discussion’s Main findings section reports greater risks of adverse maternal and offspring outcomes in pregnant women with preexisting diabetes and microvascular disease. The Results table on risk factors for progression also associates existing retinopathy and nephropathy with worsening or new-onset retinopathy during pregnancy. The claim is supported in this pregnancy-and-diabetes context. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There are insufficient data to support the use of CGM in all people with type 2 diabetes or GDM (53,54).”
What the sources say
- Not checked — no full text of the sourcecites [53] García-Moreno, 2022, Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials, Diabet Med source
- Partly supportedcites [54] Wyckoff, 2021, Time in range in pregnancy: is there a role?, Diabetes Spectr sourceExperimental — accuracy not yet measured
The section on trials in type 2 diabetes or GDM says that CGM outcomes data are far less robust, with no RCTs specifically studying type 2 diabetes in pregnancy and limited data for GDM. That supports caution about universal CGM use during pregnancy, but the source does not address all people with type 2 diabetes outside pregnancy, as the citing sentence could imply. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cost of CGM in pregnancies complicated by type 1 diabetes is offset by improved maternal and neonatal outcomes (52).”
What the sources say
- Supportedcites [52] Ahmed, 2021, The cost implications of continuous glucose monitoring in pregnant women with type 1 diabetes in 3 Canadian provinces: a posthoc cost analysis of the CONCEPTT trial, CMAJ Open source
The Interpretation conclusion says that, for pregnant patients with type 1 diabetes, governments could pay up to $1372 for CGM devices and sensors without increasing overall costs compared with SMBG, while improving maternal and neonatal outcomes. The Abstract Interpretation attributes the cost balance in part to lower neonatal intensive care costs. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In studies of individuals without preexisting diabetes, increasing A1C levels within the normal range are associated with adverse outcomes (38).”
What the sources say
- Partly supportedcites [38] Ho, 2017, Associations of mid-pregnancy HbA1c with gestational diabetes and risk of adverse pregnancy outcomes in high-risk Taiwanese women, PLoS One sourceExperimental — accuracy not yet measured
The Discussion and Results (Table 1; page numbers unavailable) associate higher mid-pregnancy HbA1c with several adverse pregnancy outcomes among women without overt diabetes, including at levels below 6.0%. The study is limited to high-risk pregnant Taiwanese women with positive glucose-challenge screens, so it does not establish the claim for individuals generally; the Discussion also describes the overall risk pattern as J-shaped, not uniformly increasing. (LLM, conf=0.85)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Observational studies in preexisting diabetes and pregnancy show the lowest rates of adverse fetal outcomes in association with A1C <6-6.5% (<42-48 mmol/mol) early in gestation (4-6,40).”
What the sources say
- Partly supportedcites [4] Jensen, 2009, Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes, Diabetes Care sourceExperimental — accuracy not yet measured
Table 1 and the Results show the lowest observed rate of serious adverse outcomes in the lowest peri-conceptional A1C category, <6.9%, among women with type 1 diabetes. The paper does not distinguish outcomes below 6–6.5% or establish that narrower range as the lowest-risk threshold; its conclusion supports a preconceptional A1C target of <7%. (LLM, conf=0.88)
- Partly supportedcites [5] Suhonen, 2000, Glycaemic control during early pregnancy and fetal malformations in women with type I diabetes mellitus, Diabetologia sourceExperimental — accuracy not yet measured
The Results (p. 3) show the lowest observed major-malformation rate in the HbA1c <5.6% group, measured before 14 weeks of gestation. This supports an association between lower early-pregnancy HbA1c and fewer malformations, but the paper does not establish a 6–6.5% cutoff or assess adverse fetal outcomes broadly; its study population was women with Type I diabetes. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [6] Nielsen, 2006, HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes, Diabetes Care source
- Not checked — no full text of the sourcecites [40] Maresh, 2015, Glycemic targets in the second and third trimester of pregnancy for women with type 1 diabetes, Diabetes Care source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
61 more claims · 35 with their cited sources checked
Create a free account to see all 103 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 37
- Probably not a substantial claim. 1
Citations
Cites
Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect
Victora, C. G., Bahl, R., Barros, A. J. D., França, G. V. A., Horton, S., Krasevec, J., Murch, S., Sankar, M. J., Walker, N., & Rollins, N. C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01024-7 · Cited by 8,040
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Weight Gain During Pregnancy: Reexamining the Guidelines
Rasmussen, K. M., & Yaktine, A. L. (2009) · Cited by 4,473
Battelino, T., Danne, T., Bergenstal, R. M., Amiel, S. A., Beck, R., Biester, T., Bosi, E., Buckingham, B. A., Cefalu, W. T., Close, K. L., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0028 · Cited by 4,237
Stagnaro-Green, A., Abalovich, M., Alexander, E., Azizi, F., Mestman, J., Negro, R., Nixon, A., Pearce, E. N., Soldin, O. P., Sullivan, S., et al. (2011) · Thyroid · doi:10.1089/thy.2011.0087 · Cited by 2,942
Alexander, E. K., Pearce, E. N., Brent, G. A., Brown, R. S., Chen, H., Dosiou, C., Grobman, W. A., Laurberg, P., Lazarus, J. H., Mandel, S. J., et al. (2017) · Thyroid® · doi:10.1089/thy.2016.0457 · Cited by 2,731
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
Rolnik, D. L., Wright, D., Poon, L. C., O’Gorman, N., Syngelaki, A., de Paco Matallana, C., Akolekar, R., Cicero, S., Janga, D., Singh, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1704559 · Cited by 2,287
Brown, M. A., Magee, L. A., Kenny, L. C., Karumanchi, S. A., McCarthy, F. P., Saito, S., Hall, D. R., Warren, C. E., Adoyi, G., & Ishaku, S. (2018) · Hypertension · doi:10.1161/hypertensionaha.117.10803 · Cited by 2,089
Metzger, B. E., Buchanan, T. A., Coustan, D. R., de Leiva, A., Dunger, D. B., Hadden, D. R., Hod, M., Kitzmiller, J. L., Kjos, S. L., Oats, J. N., et al. (2007) · Diabetes Care · doi:10.2337/dc07-s225 · Cited by 1,908
ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus
(2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002501 · Cited by 1,820
Research works printed but not linked: 2
- 2006, Dietary Reference Intakes: The Essential Guide to Nutrient Requirements
- Henderson JT , VescoKK, SengerCA, . Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality (Evidence Synthesis, no. 205). Rockville, MD, Agency for Healthcare Research and Quality. Accessed 17 October 2023. Available from https://www.ncbi.nlm.nih.gov/books/NBK574449/
Cited by
Items 101–200 of 225
The Challenges of Diagnosing Gestational Diabetes after Bariatric Surgery: Where Do We Stand?
Rodrigues-Martins, D., Nunes, I., & Monteiro, M. P. (2024) · Obesity Facts · doi:10.1159/000541623 · Cited by 6
“It is recommended that the decision of whether to use CGM in pregnant individuals with T2D or GDM should be individualized based on treatment regimen, circumstances, preferences, and needs [37].”
Medina, A. M. G., Carrillo, D. C. H., Macías, M. N. S., Soto-Chávez, M. J., Gómez, M. A. R., Parra, D., González, J. A. G., Grassi, B. A., Imitola, A., Cob, A., et al. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111902 · Cited by 5
Risk Factors and Prevention Strategies for Gestational Diabetes in Asian Populations
Pan, S.-Y., Huang, C.-J., & Cheng, H.-M. (2024) · JACC: Asia · doi:10.1016/j.jacasi.2024.08.013 · Cited by 2
Cohen, N., Toledano, Y., Shafir, M., Lavie, O., & Zilberlicht, A. (2024) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07845-z · Cited by 2
“Importantly, HbA1c testing in close proximity to the pregnant state, may be influenced by pregnancy related factors (such as increased red cell turnover, intrapartum blood loss or aberrant serum glucose levels during pregnancy), making it insensitive for 2DM detection [10].”
Navigating Automated Insulin Delivery for Type 1 Diabetes Management During Pregnancy
Scifres, C., Cleary, E. M., Sheerer, M., Bowdler, M., & Shah, V. N. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968251334597 · Cited by 3
Farladansky‐Gershnabel, S., Sachs, D. L., Qadir, N. A. E., Ram, R. B., Biron‐Shental, T., Kovo, M., & Ravid, D. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-025-08029-z · Cited by 2
Clinical features of overt versus diagnosed pre‐existing diabetes in pregnancy
Shingu, K. F., Waguri, M., Takahara, M., Katakami, N., & Shimomura, I. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70045 · Cited by 3
“Appropriate glucose and weight management after conception can reduce the risk of some perinatal complications, such as LGA 18,19 .”
Duan, B., Liu, L., Ma, C., Liu, Z., Gou, B., & Liu, W. (2025) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2025.105252 · Cited by 5
Skóra, A., Hajduk-Maślak, K., Galasińska, I., Michalik, B., Szypuła, A., & Sęk, M. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.62.006 · Cited by 3
Management of Dysglycemia in a Pregnancy Complicated by Fanconi–Bickel Syndrome
Szmuilowicz, E. D., Fruzyna, E., Madden, N., Bolden, J. R., Kozek, A., Vucko, E. R., Ghossein, C., & Barish, G. D. (2024) · AACE Clinical Case Reports · doi:10.1016/j.aace.2024.07.008 · Cited by 2
“5 These risks are substantially decreased with optimal glycemic control, 6 and glycemic targets for pregnant individuals with type 1 or type 2 diabetes 6 are shown in Table 1.”
InfluentialShestakova, M. V., Mel'nichenko, G. A., Andreeva, E. N., Sukhareva, O. Y., Vorotnikova, S. Y., Ibragimova, L. I., Фархадовна, Б. Ф., Demidova, T. Y., Геннадьевна, Д. Е., Tiselko, A. V., et al. (2024) · Diabetes Mellitus · doi:10.14341/dm13161 · Cited by 2
Hernandez, T. L., Farabi, S. S., Pelt, R. E. V., Hirsch, N. M., DUNN, E. Z., Haugen, E., Reece, M. S., Friedman, J. E., & Barbour, L. A. (2024) · Nutrients · doi:10.3390/nu16203489 · Cited by 1
“…(101.2 vs. 92.0 mg/dL) averaged across all meals Later in both the OB and NW group, respectively, were much lower than current 1 h PP and 2 h PP therapeutic targets for diabetes in pregnancy ( 140 mg/dL, 120 mg/dL, respectively [18]), and were similar to our previously reported normative data [6].”
BackgroundResultInfluentialShaat, N., Akel, O., Kristensen, K. H., Nilsson, A., Berntorp, K. E., & Katsarou, A. (2024) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14997 · Cited by 2
Liu, L., Yang, Q., Shen, P., Wang, J., Zheng, Q., Zhang, G., & Jin, B. (2024) · Journal of Biomedical Research · doi:10.7555/jbr.38.20240267 · Cited by 1
Longer Interpregnancy Interval Is Associated with Gestational Diabetes Mellitus Recurrence
Peled, T., Federmesser, D., Mazaki, E., Sela, H. Y., Grisaru‐Granovsky, S., & Rottenstreich, M. (2024) · American Journal of Perinatology · doi:10.1055/a-2480-5407 · Cited by 1
“38 Additionally, research should investigate the potential bene fi ts of targeted interventions for women with longer IPIs to prevent GDM recurrence, in fi elds of modi fi able risk factors or early GDM diagnosis.”
Diabetes and Nutrition: A Focus on Omega-3 and Omega-6 Fatty Acids
Suzuki, K., Ogawa, A., & Hara, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-32047-7_74-1 · Cited by 2
O'Flynn, J., McMorrow, R., Foley, T., Forde, R., McHugh, S., Newman, C., & Jennings, A. (2025) · HRB Open Research · doi:10.12688/hrbopenres.14022.1 · Cited by 2
“Due to the long-term risks associated with GDM and the opportunities for subsequent disease prevention, clinical practice guidelines recommend regular long-term follow-up, screening for early diagnosis of diabetes, and ongoing support for maintenance of positive health behaviours 40,45–47 .”
Contraception and Diabetes Mellitus
Panou, T., Gouveri, E., Gerede, A., Tsikouras, P. N., Papazoglou, D., & Παπάνας, Ν. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2561-9460 · Cited by 4
“Stringent glycaemic control, especially in the immediate pre-pregnancy and pregnancy period, is vital to improve pregnancy-related outcomes [1–3].”
InfluentialПрокопенко, Е. И., Фархадовна, Б. Ф., Kovalenko, T. S., & Vatazin, A. (2025) · Nephrology and Dialysis · doi:10.28996/2618-9801-2025-1-84-93 · Cited by 1
He, X., Meijing, Z., Wang, H., Xie, Y., & Zhao, H. (2025) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/ceog24123 · Cited by 3
Gestational Diabetes: From Mechanism to Therapy – A Short Review
Cursaru, R., Bratu, A., Radulian, G., Pavelescu, M. L., Rusu, E., Cirstoiu, F. C., & Cursaru, A. (2024) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2024.127.6.10 · Cited by 4
Fok, C. L., Sulley, S., Aroche, A., McDaniel, D., & Frazier, D. (2025) · Discover Public Health · doi:10.1186/s12982-025-00634-2 · Cited by 1
Yoshimura, K., Hirota, Y., Hamaguchi, T., Takeuchi, T., Takayoshi, T., Saito, S., Ueda, M., Nishikage, S., Yamamoto, A., Hashimoto, N., et al. (2025) · Journal of Diabetes Investigation · doi:10.1111/jdi.70105 · Cited by 3
“The American Diabetes Association advises against the use of metformin in pregnant women as a result of the risk of intrauterine growth retardation 27 , a concern that is particularly relevant in the care of genetic insulin resistance syndrome, given the associated high prevalence of SGA infants.”
Costa, D. N., Malek, R., & Davis, S. N. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2545929 · Cited by 2
“While insulin remains the first-line treatment for GDM, oral agents like glyburide and metformin are alternatives [6].”
Zhang, L., Zuo, L., Sun, S., Ren, Y., Gao, Y., Zhang, X., & Sun, L. (2025) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-025-07947-9 · Cited by 1
“The American Diabetes Association recommends engaging in exercise for 20–50 min per day, 2–7 days per week, at a moderate intensity [40], In contrast, the Chinese Society of Obstetrics and Gynecology suggests a minimum of 30 min of moderate intensity exercise per day, 5 days per week [42].”
Vainder, M., Natt, N., Sayyar, P., Syeda, A., Ashraf, R., Mitsakakis, N., Feig, D. S., Kingdom, J. C., & D'Souza, R. D. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14217737 · Cited by 3
“Management of diabetes in pregnancy is challenging due to limited treatment options, with insulin remaining the mainstay of therapy throughout pregnancy [5–7].”
Association Between Age at Menarche and Gestational Diabetes: A Retrospective Case–Control Study
Solis-Gómez, X., Cureño-Díaz, M. A., Olguín-Montiel, M., Jiménez, A., Gómez-Zamora, E., Leyva-López, A., Orbe-Orihuela, Y. C., Trujillo-Martínez, M., Salgado, R. C., & Hernández-Mariano, J. Á. (2025) · Women · doi:10.3390/women5040043 · Cited by 1
“Gestational diabetes mellitus (GDM) is defined as a state of hyperglycemia that appears or is first recognized during pregnancy, typically diagnosed between 24 and 28 weeks of gestation through screening and confirmatory testing [1].”
Oral Corticosteroid Use During Pregnancy and the Risk of Gestational Diabetes
Choi, E.-Y., Cho, Y., Oh, J., Choi, A., Kim, H., & Shin, J. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.6367 · Cited by 1
Jiang, X.-Y., Chen, D.-W., Duan, T., Zhang, J.-D., Ren, Y., & Tan, J. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1744305 · Cited by 4
Balcı, M. F., Akdemir, C., Yıldırım, F., Karaca, S. Y., & Karaca, I. O. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02192-3 · Cited by 2
“The 2024 ADA guidelines recommend early evaluation in high-risk pregnancies [4]; our findings suggest that incorporating lipid–glucose–derived indices into this framework could enhance early discrimination and enable timely lifestyle interventions, ultimately improving maternal and neonatal…”
InfluentialMontemayor, M. T., Ackerer, A. D., Lacroix, A., Collet, T., Dizès, O. L., Quansah, D. Y., & Puder, J. J. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109293 · Cited by 1
Arzik, I. G., Gölbaşı, H., Bayraktar, B., Aktaş, H. A., Sağlam, C., Çakır, Z. E., Ceylan, M., TUNÇEL, F., Ömeroğlu, İ., & Ekin, A. (2026) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.70960 · Cited by 2
Dang, N.-A. T., Meyrowitsch, D. W., Linde, D. S., Vinter, C. A., Nguyen, D. T., Nguyen, D. K., Ái, N. T., Le, H. M., Vũ, T. K. D., Tran, T. H., et al. (2026) · Journal of Medical Internet Research · doi:10.2196/82434 · Cited by 1
Chen, Y., Song, H., & Yang, M. (2026) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2026.2660439 · Cited by 1
Kanat, M., Abdul‐Ghani, M. A., & DeFronzo, R. A. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70987 · Cited by 1
Gestational Glucose Intolerance and the Risk of Hypertensive Disorders of Pregnancy
Maya, J., James, K. E., Schulte, C. C. M., Hsu, S. C., Thaweethai, T., Pant, D. B., Shook, L. L., Honigberg, M. C., Hivert, M., & Powe, C. E. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.125.042541 · Cited by 1
Wang, X.-H., Saeed, G., Afzal, A., Saddozai, U. A. K., Shao, G.-M., Rehman, A., Hamid, S. E., Pan, S.-Y., Ji, X., & Khawar, M. B. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1858727 · Cited by 3
“Furthermore, clinical reliance on pharmacological interventions for GDM remains complex, as glyburide has been associated with higher rates of neonatal hypoglycemia and macrosomia compared to insulin or metformin (115).”
Improved Diabetes Screening for Women After Gestational Diabetes Mellitus
Strelow, B., Herndon, J. S., McMahon, A., Takagi, M., McCoy, R. G., Olson, R., & O’Laughlin, D. J. (2024) · Diabetes Spectrum · doi:10.2337/ds24-0005 · Cited by 1
Self-citationIntrapartum Care for People with Diabetes—Working towards Evidence-Based Management
Bartal, M. F. (2024) · American Journal of Perinatology · doi:10.1055/a-2405-1846 · Cited by 3
“45 Retrospective studies evaluating the safety of continuous use of insulin pumps in pregnancy versus intravenous insulin infusion found similar outcomes.”
Diagnosis and treatment of gestational diabetes mellitus
Ko, H. S., & Choi, Y. (2024) · Journal of Korean Medical Association · doi:10.5124/jkma.2024.67.11.686 · Cited by 2
Shu, X., Yao, M., Li, C., Kang, X., Juan, J., & Yang, H. (2025) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.16191 · Cited by 2
Wang, J., Liu, Y., Cai, W., & Jiang, H. (2025) · Echocardiography · doi:10.1111/echo.70156 · Cited by 2
“Glycemic control was considered adequate if 70% or more of the reported blood glucose readings fell within normal ranges (FBG 95 mg/dL, 1hPBG 140 mg/dL, 2hPBG 121 mg/dL) [23].”
Gonçalves, J., Ferreira, H. U., Gamboa, C., Namora, G., Queirós, J. C., & Belo, S. (2025) · Diabetes Technology and Obesity Medicine · doi:10.1089/dtom.2025.0001 · Cited by 1
Pregnancy Outcomes among Adolescents and Young Adults with Diabetes in Kumasi, Ghana
Ameyaw, E., Asafo‐Agyei, S. B., Hammond, C. K., Nguah, S. B., Damalie, F. J. M. K., Senaya, C. M., & Adutwum, L. M. (2025) · GHMJ (Global Health Management Journal) · doi:10.35898/ghmj-821213 · Cited by 1
Queiroz, A. D. M., Torres, M. R. D. S., Ratis, L. C. F., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4888805/v1 · Cited by 1
Continuous and Intermittent Glucose Monitoring in 2024
Dovč, K., Bode, B. W., & Battelino, T. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8802.kd · Cited by 2
“Early detection would allow for earlier lifestyle modi fi cations, closer monitoring, and potentially even early therapeutic or lifestyle interventions to mitigate hyperglycemia exposure, all of which could contribute to better maternal and fetal outcomes (55).”
Tsushima, R., Ito, A., Oishi, M., Ishihara, K., Iino, K., Tanaka, K., & Yokoyama, Y. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15072634
“The American Diabetes Association (ADA) recommends a 75 g oral glucose tolerance test (OGTT) at 4–12 weeks postpartum, followed by ongoing glycemic screening every 1–3 years [13].”
Sereika, S. M., MOORE, K. R., STOTZ, S. A., Chalmers, L. J., Garrow, H., Gonzales, K. L., O’Banion, N., Powell, J., Knoki‐Wilson, U., Charron‐Prochownik, D., et al. (2024) · Journal of Midwifery & Women s Health · doi:10.1111/jmwh.13643
Fetal size monitoring in women with gestational diabetes and normal glucose tolerance
Beunen, K., den Abbeele, F. V., Crombrugge, P. V., Verhaeghe, J., Vandeginste, S., Verlaenen, H., Maes, T., Dufraimont, E., Roggen, N., Block, C. E. M. D., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02330-0
“After GDM diagnosis, lifestyle behavior change including dietary counseling and modifica - tion, physical activity, glucose and weight monitoring with close follow-up is essential to manage maternal glycemia [5].”
Evaluation of a Standardized Obstetrics Insulin Drip Protocol and Order Set
Davis, M., Naseman, K., Leung, N. R., & Schadler, A. D. (2024) · Diabetes Spectrum · doi:10.2337/ds24-0011
Utilizing the glucose challenge test during pregnancy as a predictor of future diabetes risk
Frankel, M., Tsur, N., Pollack, R. M., & Tsur, A. (2024) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-024-06874-5 · Cited by 3
Protocolo diagnóstico y terapéutico de la diabetes en el embarazo
Cebada, A. B., Silva, J. B. Q., Escobar-Morreale, H. F., et al. (2024) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2024.10.013
For Gestational Diabetes Pharmacotherapy, Insulin Reigns Supreme
Powe, C. E. (2025) · JAMA · doi:10.1001/jama.2024.27148
Lilliecreutz, C., Söderström, E., Ersson, M., Bendtsen, M., Brown, V., Kaegi-Braun, N., Linder, R., Maddison, R., Chisalita, S. I., & Löf, M. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-089355 · Cited by 2
“13 Indeed, diet and physical activity modifications are sufficient to control glycaemic status in 70%–85% of women with GDM 3 and have proven effective in decreasing maternal and foetal morbidity.”
Fincher, K., Fiocchi, C., ODOM, J. M., STANCIL, M. D., White, H., & Schellinger, M. M. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0052 · Cited by 1
Nutritional Management and Updates of Diabetes in Pregnancy
Faizullabhoy, A. (2025) · ADCES in Practice · doi:10.1177/2633559x251328892
Jiang, X., Mao, X., Li, X., Tang, Y., Qu, X., Su, P., Li, L., & Liu, X. (2025) · Research Square · doi:10.21203/rs.3.rs-6372507/v1
Xue, Y., Juan, J., Shu, X., et al. (2025) · PeerJ · doi:10.7717/peerj.19502
Shaheen, N., Sajjad, R., Ashraf, V., Uzma, S., & Hayat, N. (2025) · Pakistan Journal of Health Sciences · doi:10.54393/pjhs.v6i5.2757
Kang, B. S., Yu, J., Kim, K., Yun, J.-S., Lee, Y. J., Ko, H. S., & Choi, Y.-H. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090775 · Cited by 1
Sue-Nagumo, M., Morita, A., Higeta, D., Inoue, M., Osaki, A., Yoshino, S., Matsumoto, S., Horiguchi, K., Okada, S., Iwase, A., et al. (2025) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.2025.j080
Reguera‐Hernández, C., Valdez‐González, J., Garza‐Silva, A., Fernández‐Chau, I. F., Moreno-Estrada, L. A., Garza‐Rodríguez, C., González‐Cantú, A., Sanz‐Sánchez, M. Á., Rivera-Cavazos, A., & Romero-Ibarguengoitia, M. E. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01662-0
“The clinical guidelines of the American College of Obstetricians and Gynecologists (ACOG) and the American Diabetes Association (ADA) recommend a HbA1c target of less than 6.0% (or less than 6.5% if there is a risk of maternal hypoglycemia) to reduce the risk of macrosomia [14, 15].”
InfluentialChen, H., Du, J., Wang, X., Cui, L., Wu, Q., Zhu, Y., & Guo, Y. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118810 · Cited by 1
Zhu, T., Dong, Y., Ding, Z., et al. (2025) · Research Square · doi:10.21203/rs.3.rs-6639941/v1
Prevalence and Predictors of Post-coital Hypoglycemia in Diabetes Mellitus
AlJabr, Q., Bu-khamseen, A. A., Alalawi, M., Alkuwaiti, A. A., Aldhneen, B. A., Al-Shehab, F. J., Ameer, H. A., Dakhlan, F. A., Albaqshi, N. K., & Bu-Khamsin, A. A. (2025) · Cureus · doi:10.7759/cureus.91290
“However, these medications have low intrinsic risk of hypoglycemia when prescribed as monotherapy [23,24].”
Jaziri, Z. A., Alshayeb, Z. K., Bubshait, A. A., & Alhodibi, M. (2025) · Cureus · doi:10.7759/cureus.91595 · Cited by 2
Nunlee‐Bland, G., Mitchell, R. D., Reeves, I. V., & Young, M. A. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0034 · Cited by 1
Reproductive Health Counseling in the T1D Exchange Quality Improvement Collaborative
O’Malley, G., OGYAADU, S. J., Levister, C. M., Rioles, N. A., Hardison, H., Roberts, A. J. C., Accacha, S. D., Guttmann‐Bauman, I., Vendrame, F., Fallurin, R., et al. (2025) · Diabetes Spectrum · doi:10.2337/ds25-0002
Lininger, J., Phonyiam, R., & Terathongkum, S. (2025) · Women s Health Reports · doi:10.1177/26884844251383424
“1 However, these efforts are often complicated by pregnancy ’ s physical and emotional burdens, underscoring the importance of continuous support from health care providers and family members to ensure adherence to diabetes management protocols.”
Kang, H. S., Park, H. R., Kang, J., & Kim, C. (2025) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106251378719 · Cited by 2
“12-15 Current evidence highlights the positive impact of CGM on glucose management.”
Helvacı, B. C., Candemir, B., Cinel, M., Hepşen, S., Canlar, Ş., Dağdeviren, M., & Çakal, E. (2025) · Turkish Journal of Diabetes and Obesity · doi:10.25048/tudod.1701369 · Cited by 1
Prokopenko, E. I., Vatazin, A., Георгиевна, Н. И., Фархадовна, Б. Ф., Kovalenko, T. S., & Владимировна, Г. Д. (2025) · Nephrology and Dialysis · doi:10.28996/2618-9801-2025-3-258-268
Metabolic Harmony: Nourishing Solutions for Managing Diabetes Mellitus Through Nutrition
Mitra, A. K., & Haq, T. (2025) · Nutrition and health · doi:10.1007/978-3-031-95373-6_3
Response to: "Contraceptive safety in liver disease: The cost of overstating risk"
Phaloprakarn, C., Tangjitgamol, S., Sethasine, S., et al. (2025) · Contraception · doi:10.1016/j.contraception.2025.111048
The most common endocrine disorders in pregnancy
Milovanović, Z., & Filimonović, D. (2025) · Medicinski podmladak · doi:10.5937/mp76-47814
Gestational Diabetes and Type 2 Diabetes during Pregnancy
Bond, R., & Peters, T. M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-23940-3.00050-8
Jelliffe‐Pawlowski, L. L., Lab, H., Baer, R. J., Oltman, S. P., McKenzie‐Sampson, S., Adeyemi, D., Becker, A., Blackman, K. C. A., Blebu, B. E., Brandt, J. S., et al. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-09517-z
“This will be a very important area of investigation moving forward, as what constitutes “actionable risk” in these groups is strongly tied to severity [41, 43, 44, 61, 62, 66].”
Quansah, D. Y., Arhab, A., & Puder, J. J. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00240-w
“Gestational diabetes mellitus (GDM) is referred to as hyperglycemia first diagnosed during pregnancy without fulfilling the criteria for pre-existing diabetes [1].”
InfluentialAkbağ, N. N. A., & Tokat, M. A. (2025) · Health Care For Women International · doi:10.1080/07399332.2025.2597240
Yüksek Riskli Bir Gebenin Spiritüel Ebelik Bakım Gereksinimlerinin Belirlenmesi: Bir Olgu Sunumu
Demirci, G., & Koç, Z. (2025) · Gümüşhane Üniversitesi Sağlık Bilimleri Dergisi · doi:10.37989/gumussagbil.1728440
Chen, Y.-F., & Wang, L.-H. (2025) · Gynecological Endocrinology · doi:10.1080/09513590.2025.2607806
Bradford, H. M., Arrington, L., Suh, C., Katoch, A., Hernandez, N., Bhatt, M., Bower, K. M., Clark, E. V., Eagen‐Torkko, M. K., Shasanmi, R. O., et al. (2025) · Health Equity · doi:10.1177/24731242251400589 · Cited by 1
From Diagnosis to Delivery: A Look at the Continuing Gap in Maternal Testing
Torres, C., Kelly, J., & Gronowski, A. M. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvaf109
Whelan, J., & Kole‐White, M. B. (2025) · Contemporary surgical clerkships · doi:10.1007/978-3-031-96541-8_19
Pandit, R., Drusini, F. S., Wu, J., Guhde, H., Nwosu, O., Kinghorn, T. E., Steinbrunner, A., Gregory, D., Vickers, S., Landon, M. B., et al. (2026) · American Journal of Perinatology · doi:10.1055/a-2788-1901
Su, Y., Yang, Q. Z., Xing, C., Wang, H., Li, R., Zhang, J., Mei, J., & He, J. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/2596620
“Lu et al. [15], employing Mendelian randomization analysis, demonstrated that genetic polymorphisms predisposing to early menarche are independently associated with an increased risk of GDM, which is consistent with our fi ndings.”
Gossen-Perez, E., Minglan, L., Lewis-Hills, E., Okesene-Gafa, K. A. M., & Oyston, C. (2026) · Discover Endocrinology and Metabolism · doi:10.1007/s44417-025-00013-0
Lacerda, A. S., dos Santos, K., da Silva, L. B. G., Zajdenverg, L., Bittencourt, K., Marvila, K., Rodrigues, L. R., Almeida, M., & Saunders, C. (2026) · Nutrition · doi:10.1016/j.nut.2026.113159
Fialho, T. A. H., Lacerda, S. C. D., Bezerra, M. M. A., Nardi, J. R., Magalhães, A. W. D., Oliveira, G. G. B. D., & Ferraz, J. G. D. (2026) · LUMEN ET VIRTUS · doi:10.56238/levv17n58-006
Maternal serum NRF2 at 12 weeks as a biomarker for development of gestation diabetes mellitus
Ge, J., Jia, X., Tang, W., Lu, D., & Wang, L. (2026) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-026-08327-0
Early meal timing improves nocturnal glucose in pregnancies complicated by gestational diabetes
Cunningham, H. A., Ward, L., Butler, M. P., & Valent, A. M. (2026) · Diabetologia · doi:10.1007/s00125-026-06701-w · Cited by 3
“Lifestyle modifications, including exercise and medical nutrition therapy, are first-line interventions in GDM management to reduce hyperglycaemia and associated pregnancy complications [3, 4].”
Lumu, W., Nakireka, S., Mutebi, R. K., Ndiwalana, R. B., Muyanja, D., Nassejje, G., Nabukalu, H., Mayega, R., Munvaneza, D., Nakacwa, S., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8775786/v1
Elkind-Hirsch, K. E., Armatta, M., VEILLON, E. W., Jr., Schiavon, S., & Cappon, G. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-08944-2
Testing the feasibility of an intermittent low‐energy diet in women with gestational diabetes
Dapre, E., Barrett, E., McMillan, B., Pilkington, A., Hanna, F., Vyas, A., Lombardelli, C., Mubita, W., Athirampuzha, J., Dosanjh, L., et al. (2026) · Diabetic Medicine · doi:10.1111/dme.70258
“8 A possible dietary approach is an intermittent low-energy diet (ILED) which includes several days of a low-energy diet (650–1000 kcal) with normal eating on other days.”
Smith, B. P., Greenberg, M., Scandurro, A., Bandera, H. S., Millman, A. K., Garrison, S. L., Haynes, S. C., Zhu, Y., Ferrara, A. M., & Brown, S. D. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doc25-0034
Scairati, R., Newman, C., Alvarez‐Iglesias, A., Smyth, A., O’Shea, P. M., Devane, D., Gillespie, P., Egan, A. M., O'Donnell, M. J., & Dunne, F. (2026) · Trials · doi:10.1186/s13063-026-09703-6 · Cited by 1
Pregnancies Affected by Diabetes in Teenagers and Emerging Adults: A Population-Based Study
Christie, H. E., Zimmowitch, A., Mohan, S., Enriquez, L. P., Pone, K. A., Cooper, K., Vella, A. V., Creo, A. L., & Egan, A. M. (2026) · Metabolic Syndrome and Related Disorders · doi:10.1177/15578518261445043
“10,33 However, in our cohort, only 52.9% of teens and emerging adults with pregestational diabetes were prescribed contraceptive prior to conception, and only 11.8% had a preconception HbA1c below 48 mmol/mol (6.5%).”
InfluentialXie, X., Zeng, L., Zhao, X., Wang, Y., Lian, X., Lin, Z., & Wu, W. (2026) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-026-08974-w
“GDM is associated with increased risks such as spontaneous abortion, fetal malformation, preeclampsia, caesarean section, macrosomia, neonatal hypoglycemia, and neonatal respiratory distress syndrome [3, 4].”
Prevention of Obesity and Excessive Gestational Weight Gain in Pregnancy
Gilboa, I., & Yogev, Y. (2026) · Springer eBooks · doi:10.1007/978-3-032-23479-7_16
Metadata
- Authors
- American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., Lingvay, I., Matfin, G., McCoy, R. G., Perry, M. L., Pilla, S. J., Polsky, S., Prahalad, P., Pratley, R. E., Segal, A. R., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
- ORCID
- ElSayed, Nuha A.
- Aleppo, Grazia
- Bannuru, Raveendhara R.
- Bruemmer, Dennis
- Collins, Billy S.
- Ekhlaspour, Laya
- Hilliard, Marisa E.
- Johnson, Eric L.
- Khunti, Kamlesh
- Lingvay, Ildiko
- McCoy, Rozalina G.
- Perry, Mary Lou
- Pilla, Scott J.
- Polsky, Sarit
- Prahalad, Priya
- Pratley, Richard E.
- Segal, Alissa R.
- Seley, Jane Jeffrie
- Stanton, Robert C.
- Gabbay, Robert A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2023-12-11
- Volume
- 47
- Issue
- Supplement_1
- Pages
- S282-S294
- ISSN
- 0149-5992 (ISSN-L)
- PMC
- PMC10725801
- OpenAlex
- W4389560993
- Semantic Scholar
- 1f3e4a9c0ae2be86d5da282aa96908a6bda368a2
- Cited by
- 232
- References
- 147
- Citations by year
- 2026: 60 · 2025: 106 · 2024: 66
- FWCI
- 14.10
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- diabetes in pregnancy, gestational diabetes mellitus, clinical guidelines, treatment goals, quality of care
- MeSH terms
- Diabetes Mellitus, Endocrinology, Female, Humans, Pregnancy, Reference Standards, Societies, Medical, Standard of Care
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.